Form 483

GP PHARM S.A.U. Form 483, 2019-05-21

FDA issued a Form 483 to GP PHARM S.A.U. on 2019-05-21 with 16 public-safe observations.

483· Form 483 issuedHuman Drugs16 observations

GP PHARM S.A.U. · Sant Quinti De Mediona, Spain · Issued May 21, 2019

Overview

  • 16 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 May 2019
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Cheryl A Clausen, Zhihao Pete Qiu

21 May 2019
21 CFR 211.110(b)

In-process conformity - examination, sample testing

Cited by Cheryl A Clausen, Zhihao Pete Qiu

21 May 2019
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Cheryl A Clausen, Zhihao Pete Qiu

21 May 2019
21 CFR 211.188(b)

Batch production and Batch Control Record Requirements

Cited by Cheryl A Clausen, Zhihao Pete Qiu

21 May 2019
21 CFR 211.194(a)

Complete test data included in records

Cited by Cheryl A Clausen, Zhihao Pete Qiu

Inspected site

GPGP PHARM S.A.U.Sant Quinti De Mediona, Spain

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations2x
21 CFR 211.110(b)Cited across public-safe Form 483 observations2x
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.188(b)Cited across public-safe Form 483 observations2x
21 CFR 211.194(a)Cited across public-safe Form 483 observations2x
21 CFR 211.22(a)Cited across public-safe Form 483 observations2x
21 CFR 211.25(a)Cited across public-safe Form 483 observations2x
21 CFR 211.67(a)Cited across public-safe Form 483 observations2x

Full 483 report

Get the verbatim text of all 16 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere